Nerlynx Approved by FDA for HER2-positive Breast Cancer Patients to Reduce Risk of Recurrence
News
The U.S. Food and Drug Administration (FDA) approved Puma Biotechnology‘s Nerlynx (neratinib) as an extended adjuvant treatment of early-stage, HER2-positive breast cancer. This means that Nerlynx is the first extended adjuvant therapy for ... Read more